CTRP Terminology
CTRP Agent Terminology
NCIt Antineoplastic Agent Terminology
Pyrimidine Antagonist
GDC Terminology
GDC Therapeutic Agent Terminology
NCI Drug Dictionary Terminology
GDC Value Terminology
Pharmacologic Substance
FDA Established Names and Unique Ingredient Identifier Codes Terminology
2'-F-ara-deoxyuridine
1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl) Uracil
1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl) uracil
1-(2-DEOXY-2-FLUORO-.BETA.-D-ARABINOFURANOSYL)URACIL
2'-F-ara-deoxyuridine
2'-F-ara-deoxyuridine
2'-F-ara-deoxyuridine
2'-F-ara-deoxyuridine
616102
616102
616102
69123-94-0
A deoxyuridine prodrug with potential antineoplastic activity. Upon cellular uptake, 2'-F-ara-deoxyuridine (FAU) is phosphorylated by thymidine kinase to FAU monophosphate and subsequently methylated in the 5'-position by thymidylate synthase (TS) to its activated form, 1-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl) 5-methyluracil monophosphate (FMAUMP). FMAUMP is incorporated into DNA leading to an inhibition of DNA synthesis and so cell growth. The catalytic activity of TS is critical to activation of FAU and subsequent incorporation into DNA. FAU may be beneficial in the case of tumors with high TS activity that are resistant to TS inhibitors.
A substance being studied in the treatment of advanced solid tumors and lymphomas. It blocks the growth of cells and may cause cancer cells to die. It is a type of uracil analog.
C80036
C9H11FN2O5
CL388502
CTRP
FAU
FDA
GDC
K7386OMP29
Nucleic Acid, Nucleoside, or Nucleotide
Pharmacologic Substance
_2-F-ara-deoxyuridine